Decrease in venous irritation by adjusting the concentration of injected bendamustine

Hiroyuki Watanabe, Hiroaki Ikesue, Tomoko Tsujikawa, Kenichiro Nagata, Mayako Uchida, Kimitaka Suetsugu, Nobuaki Egashira, Tsuyoshi Muta, Koji Kato, Katsuto Takenaka, Saiji Ohga, Takamitsu Matsushima, Motoaki Shiratsuchi, Toshihiro Miyamoto, Takanori Teshima, Koichi Akashi, Ryozo Oishi

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Intravenous injection of bendamustine often causes venous irritation and also deteriorates the patient's quality of life. Thus, we evaluated the risk factors associated with venous irritation induced by bendamustine in patients with follicular lymphoma or mantle cell lymphoma. We also evaluated the effectiveness of intervention of changing the preparation procedure for bendamustine. All data were retrospectively collected from the electronic medical record system. In the initial analysis of the total 43 courses of bendamustine therapy, most patients (88%) were administered bendamustine with 250 mL of diluent according to the bendamustine package insert in Japan. The median concentration of bendamustine solution (0.56 mg/mL vs. 0.24 mg/mL) and the incidences of venous irritation (66% vs. 0%, p= 0.01) were significantly different between the patients receiving bendamustine at 250 mL and 500 mL of diluent. Based on this result, we proposed changing the final volume of bendamustine dissolution from 250 to 500 mL, which is recommended in other countries. After this intervention, the incidence of venous irritation was significantly reduced from 58 to 20% ( p= 0.02). The incidence of venous irritation increased in a concentration-dependent manner (≤0.40 mg/mL: 6%; 0.41-0.60 mg/mL: 62%, p<0.001; >0.60 mg/mL: 75%, p<0.001). We conclude that a high concentration bendamustine solution is a risk factor for venous irritation and that 500 mL of diluent is ideal. To further reduce the incidence of venous irritation, the concentration of bendamustine solution is recommended to be 0.40 mg/mL or less.

元の言語英語
ページ(範囲)574-578
ページ数5
ジャーナルBiological and Pharmaceutical Bulletin
36
発行部数4
DOI
出版物ステータス出版済み - 4 1 2013

Fingerprint

Incidence
Bendamustine Hydrochloride
Product Labeling
Mantle-Cell Lymphoma
Follicular Lymphoma
Electronic Health Records
Intravenous Injections
Japan
Quality of Life
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

これを引用

Watanabe, H., Ikesue, H., Tsujikawa, T., Nagata, K., Uchida, M., Suetsugu, K., ... Oishi, R. (2013). Decrease in venous irritation by adjusting the concentration of injected bendamustine. Biological and Pharmaceutical Bulletin, 36(4), 574-578. https://doi.org/10.1248/bpb.b12-00901

Decrease in venous irritation by adjusting the concentration of injected bendamustine. / Watanabe, Hiroyuki; Ikesue, Hiroaki; Tsujikawa, Tomoko; Nagata, Kenichiro; Uchida, Mayako; Suetsugu, Kimitaka; Egashira, Nobuaki; Muta, Tsuyoshi; Kato, Koji; Takenaka, Katsuto; Ohga, Saiji; Matsushima, Takamitsu; Shiratsuchi, Motoaki; Miyamoto, Toshihiro; Teshima, Takanori; Akashi, Koichi; Oishi, Ryozo.

:: Biological and Pharmaceutical Bulletin, 巻 36, 番号 4, 01.04.2013, p. 574-578.

研究成果: ジャーナルへの寄稿記事

Watanabe, H, Ikesue, H, Tsujikawa, T, Nagata, K, Uchida, M, Suetsugu, K, Egashira, N, Muta, T, Kato, K, Takenaka, K, Ohga, S, Matsushima, T, Shiratsuchi, M, Miyamoto, T, Teshima, T, Akashi, K & Oishi, R 2013, 'Decrease in venous irritation by adjusting the concentration of injected bendamustine', Biological and Pharmaceutical Bulletin, 巻. 36, 番号 4, pp. 574-578. https://doi.org/10.1248/bpb.b12-00901
Watanabe, Hiroyuki ; Ikesue, Hiroaki ; Tsujikawa, Tomoko ; Nagata, Kenichiro ; Uchida, Mayako ; Suetsugu, Kimitaka ; Egashira, Nobuaki ; Muta, Tsuyoshi ; Kato, Koji ; Takenaka, Katsuto ; Ohga, Saiji ; Matsushima, Takamitsu ; Shiratsuchi, Motoaki ; Miyamoto, Toshihiro ; Teshima, Takanori ; Akashi, Koichi ; Oishi, Ryozo. / Decrease in venous irritation by adjusting the concentration of injected bendamustine. :: Biological and Pharmaceutical Bulletin. 2013 ; 巻 36, 番号 4. pp. 574-578.
@article{f1b9d40394b343ce8eac24830cc46eed,
title = "Decrease in venous irritation by adjusting the concentration of injected bendamustine",
abstract = "Intravenous injection of bendamustine often causes venous irritation and also deteriorates the patient's quality of life. Thus, we evaluated the risk factors associated with venous irritation induced by bendamustine in patients with follicular lymphoma or mantle cell lymphoma. We also evaluated the effectiveness of intervention of changing the preparation procedure for bendamustine. All data were retrospectively collected from the electronic medical record system. In the initial analysis of the total 43 courses of bendamustine therapy, most patients (88{\%}) were administered bendamustine with 250 mL of diluent according to the bendamustine package insert in Japan. The median concentration of bendamustine solution (0.56 mg/mL vs. 0.24 mg/mL) and the incidences of venous irritation (66{\%} vs. 0{\%}, p= 0.01) were significantly different between the patients receiving bendamustine at 250 mL and 500 mL of diluent. Based on this result, we proposed changing the final volume of bendamustine dissolution from 250 to 500 mL, which is recommended in other countries. After this intervention, the incidence of venous irritation was significantly reduced from 58 to 20{\%} ( p= 0.02). The incidence of venous irritation increased in a concentration-dependent manner (≤0.40 mg/mL: 6{\%}; 0.41-0.60 mg/mL: 62{\%}, p<0.001; >0.60 mg/mL: 75{\%}, p<0.001). We conclude that a high concentration bendamustine solution is a risk factor for venous irritation and that 500 mL of diluent is ideal. To further reduce the incidence of venous irritation, the concentration of bendamustine solution is recommended to be 0.40 mg/mL or less.",
author = "Hiroyuki Watanabe and Hiroaki Ikesue and Tomoko Tsujikawa and Kenichiro Nagata and Mayako Uchida and Kimitaka Suetsugu and Nobuaki Egashira and Tsuyoshi Muta and Koji Kato and Katsuto Takenaka and Saiji Ohga and Takamitsu Matsushima and Motoaki Shiratsuchi and Toshihiro Miyamoto and Takanori Teshima and Koichi Akashi and Ryozo Oishi",
year = "2013",
month = "4",
day = "1",
doi = "10.1248/bpb.b12-00901",
language = "English",
volume = "36",
pages = "574--578",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "4",

}

TY - JOUR

T1 - Decrease in venous irritation by adjusting the concentration of injected bendamustine

AU - Watanabe, Hiroyuki

AU - Ikesue, Hiroaki

AU - Tsujikawa, Tomoko

AU - Nagata, Kenichiro

AU - Uchida, Mayako

AU - Suetsugu, Kimitaka

AU - Egashira, Nobuaki

AU - Muta, Tsuyoshi

AU - Kato, Koji

AU - Takenaka, Katsuto

AU - Ohga, Saiji

AU - Matsushima, Takamitsu

AU - Shiratsuchi, Motoaki

AU - Miyamoto, Toshihiro

AU - Teshima, Takanori

AU - Akashi, Koichi

AU - Oishi, Ryozo

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Intravenous injection of bendamustine often causes venous irritation and also deteriorates the patient's quality of life. Thus, we evaluated the risk factors associated with venous irritation induced by bendamustine in patients with follicular lymphoma or mantle cell lymphoma. We also evaluated the effectiveness of intervention of changing the preparation procedure for bendamustine. All data were retrospectively collected from the electronic medical record system. In the initial analysis of the total 43 courses of bendamustine therapy, most patients (88%) were administered bendamustine with 250 mL of diluent according to the bendamustine package insert in Japan. The median concentration of bendamustine solution (0.56 mg/mL vs. 0.24 mg/mL) and the incidences of venous irritation (66% vs. 0%, p= 0.01) were significantly different between the patients receiving bendamustine at 250 mL and 500 mL of diluent. Based on this result, we proposed changing the final volume of bendamustine dissolution from 250 to 500 mL, which is recommended in other countries. After this intervention, the incidence of venous irritation was significantly reduced from 58 to 20% ( p= 0.02). The incidence of venous irritation increased in a concentration-dependent manner (≤0.40 mg/mL: 6%; 0.41-0.60 mg/mL: 62%, p<0.001; >0.60 mg/mL: 75%, p<0.001). We conclude that a high concentration bendamustine solution is a risk factor for venous irritation and that 500 mL of diluent is ideal. To further reduce the incidence of venous irritation, the concentration of bendamustine solution is recommended to be 0.40 mg/mL or less.

AB - Intravenous injection of bendamustine often causes venous irritation and also deteriorates the patient's quality of life. Thus, we evaluated the risk factors associated with venous irritation induced by bendamustine in patients with follicular lymphoma or mantle cell lymphoma. We also evaluated the effectiveness of intervention of changing the preparation procedure for bendamustine. All data were retrospectively collected from the electronic medical record system. In the initial analysis of the total 43 courses of bendamustine therapy, most patients (88%) were administered bendamustine with 250 mL of diluent according to the bendamustine package insert in Japan. The median concentration of bendamustine solution (0.56 mg/mL vs. 0.24 mg/mL) and the incidences of venous irritation (66% vs. 0%, p= 0.01) were significantly different between the patients receiving bendamustine at 250 mL and 500 mL of diluent. Based on this result, we proposed changing the final volume of bendamustine dissolution from 250 to 500 mL, which is recommended in other countries. After this intervention, the incidence of venous irritation was significantly reduced from 58 to 20% ( p= 0.02). The incidence of venous irritation increased in a concentration-dependent manner (≤0.40 mg/mL: 6%; 0.41-0.60 mg/mL: 62%, p<0.001; >0.60 mg/mL: 75%, p<0.001). We conclude that a high concentration bendamustine solution is a risk factor for venous irritation and that 500 mL of diluent is ideal. To further reduce the incidence of venous irritation, the concentration of bendamustine solution is recommended to be 0.40 mg/mL or less.

UR - http://www.scopus.com/inward/record.url?scp=84876939751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876939751&partnerID=8YFLogxK

U2 - 10.1248/bpb.b12-00901

DO - 10.1248/bpb.b12-00901

M3 - Article

C2 - 23392075

AN - SCOPUS:84876939751

VL - 36

SP - 574

EP - 578

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 4

ER -